OraSure Technologies, Inc.
OSUR
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $239.6M
$3.48
▼ -2.79%
P/E
-5.04
Mkt Cap
$239.6M
52-Wk Range
$2.08–$4.58
52-Week Range
$2.08 - $4.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oral fluid collection and testing technology with established market leadership in rapid HIV diagnostics
- Diversified product portfolio spanning infectious disease, drug screening, genomics, and molecular testing reducing revenue concentration
- Strong distribution network including clinical laboratories, hospitals, government agencies, and direct-to-consumer channels
- FDA-cleared and internationally recognized diagnostic products with established clinical credibility and regulatory pathways
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Expanding demand for point-of-care and at-home diagnostic testing driven by consumer preference for accessible healthcare solutions
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Weak
-16.1% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OSUR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.09 vs -$0.27 consensus (+133.3% surprise). Revenue of $30.6M vs $29.1M expected (+5.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+133.3%
Revenue trend · last 8Q
—
-51%
-45%
-43%
-32%
-29%
-7%
-189%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$39.9M
$37.4M
$29.9M
$31.2M
$27.1M
$26.8M
$27.9M
-$27.9M
Margins · last 8Q
Gross
37.4%
Operating
-83.1%
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How OSUR stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related